United Statesbellcocapital.com
Its role Developer
Bellco Capital is a private direct investment firm and single family office headquartered in Los Angeles, California. Founded in 2003 by biotechnology entrepreneurs Rebecka Belldegrun, M.D., who serves as CEO, and Arie Belldegrun, M.D., FACS, the firm focuses on deploying capital to support companies and initiatives with ambitions for exponential transformation, primarily in life sciences, real estate, consumer products, and media.
The firm has built a notable track record in biotechnology, particularly cell and gene therapies. Prominent investments and co-foundings include Kite Pharma, acquired by Gilead Sciences in 2017 for $11.9 billion, and Allogene Therapeutics, which completed a major IPO. Additional portfolio companies include entities in therapeutics, drug discovery, and related innovative technologies across North America and select international markets.
In the real estate sector, Bellco Capital serves as the joint-venture partner with Tishman Speyer in Breakthrough Properties, a specialized platform for acquiring, developing, and operating life science properties. This collaboration leverages Bellco’s biotech expertise alongside Tishman Speyer’s global real estate capabilities to deliver Class A lab, research, and innovation facilities in key clusters such as Boston, San Diego, Seattle, and European locations.
Operating as a family office with a long-term perspective, Bellco Capital emphasizes relationship-driven investments, integrity, and cross-sector collaboration. It positions itself as a bridge between biotechnology entrepreneurship and specialized real estate investment, supporting scientific innovation and the growth of mission-driven companies in the life sciences industry.
Also known as Bellco.
chemXplore tracks 1 project involving Bellco Capital.
Group sales +6% (CER) in first nine months; Q3 +7% (CER)/+8% CHF. Pharmaceuticals drove growth, diagnostics up despite China pricing reforms. 2026 outlook confirmed.
active all projects
